12:00 AM
Jul 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Rhucin: Completed Phase III enrollment

Pharming completed enrollment of 75 patients in the double-blind, placebo-controlled, U.S. Phase III Study 1310 trial evaluating IV Rhucin. Patients weighing <84 kg will receive 50 units/kg of Rhucin and those weighing >=84 kg will receive 4,200 units of Rhucin. The trial will continue until either all patients have received treatment for a repeat HAE attack or achieved a 90-day attack-free period. Pharming said 53 patients have experienced...

Read the full 320 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >